{"id":"NCT00759291","sponsor":"Brigham and Women's Hospital","briefTitle":"The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome","officialTitle":"The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-04-01","primaryCompletion":"2017-12-01","completion":"2017-12-30","firstPosted":"2008-09-25","resultsPosted":"2023-02-21","lastUpdate":"2023-02-21"},"enrollment":40,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Metabolic Syndrome"],"interventions":[{"type":"DRUG","name":"acipimox","otherNames":["Olbetam"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Acipimox","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.","primaryOutcome":{"measure":"Flow Mediated Vasodilation","timeFrame":"After 7 days of each treatment.","effectByArm":[{"arm":"Metabolic Syndrome","deltaMin":9.5,"sd":6.5},{"arm":"Control","deltaMin":10.8,"sd":4.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["31571412","39888728"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":[]}}